| Literature DB >> 23771720 |
Shabina A Hayat1, Robert Luben2, Victoria L Keevil2, Stephanie Moore2, Nichola Dalzell2, Amit Bhaniani2, Anthony P Khawaja2, Paul Foster2, Carol Brayne2, Nicholas J Wareham2, Kay-Tee Khaw2.
Abstract
The European Prospective Investigation of Cancer (EPIC) is a 10-country collaborative study in which EPIC-Norfolk is one of the UK centres. EPIC-Norfolk examined 25 639 men and women resident in East Anglia (aged 40-79 years), between 1993 and 1997. The EPIC collaboration was set up to examine the dietary determinants of cancer, but the remit in the EPIC-Norfolk cohort was broadened from the outset to include determinants of other health conditions and chronic diseases. EPIC-Norfolk completed a third round of health examinations (EPIC-Norfolk 3 or 3HC) in December 2011, on 8623 participants in the age range 48-92 years. EPIC-Norfolk focused on objective measures of cognitive function, physical capability and visual health, adapting this existing mid-life cohort to the current need to investigate healthy and independent living for ageing societies. With a wealth of longitudinal data and a biobank (including DNA) collected at up to three separate time points, EPIC-Norfolk offers the unique opportunity to investigate the association of lifestyle and biological factors, including genetic exposures, with a range of health outcomes in middle and later life. Information for data access can be found on the study website, details as given in this cohort profile. Published by Oxford University Press on behalf of the International Epidemiological AssociationEntities:
Mesh:
Year: 2013 PMID: 23771720 PMCID: PMC4121549 DOI: 10.1093/ije/dyt086
Source DB: PubMed Journal: Int J Epidemiol ISSN: 0300-5771 Impact factor: 7.196
Age and sex of responders and non-responders at baseline
| Variable | Responders | Non responders |
|---|---|---|
| 39% ( | 61% ( | |
| % ( | 36.2 (13 700) | 63.8 (24 125) |
| Age group (years) | ||
| ≤44 | 4.3 (587) | 6.5 (1572) |
| 45-49 | 16.7 (2287) | 21.0 (5061) |
| 50-54 | 15.9 (2178) | 18.2 (4385) |
| 55-59 | 15.2 (2075) | 15.1 (3649) |
| 60-64 | 15.6 (2142) | 13.1 (3165) |
| 65-69 | 15.4 (2112) | 11.8 (2848) |
| ≥70 | 16.9 (2319) | 14.3 (3445) |
| % ( | 42.1 (16 745) | 57.9 (23 060) |
| Age group (years) | ||
| ≤44 | 4.6 (778) | 6.2 (1422) |
| 45-49 | 18.4 (3084) | 18.7 (4304) |
| 50-54 | 16.1 (2699) | 16.1 (3717) |
| 55-59 | 15.1 (2523) | 13.8 (3189) |
| 60-64 | 14.8 (2482) | 13.0 (3009) |
| 65-69 | 14.9 (2492) | 13.4 (3080) |
| ≥70 years | 16.1 (2687) | 18.8 (4339) |
Figure 1.EPIC-Norfolk study over more than 18 years of follow up, showing numbers of participants who responded positively and attended health examinations and those lost to follow up at each phase
*These 7547 participants consented to take part at baseline (of which 5970 attended 1HC), but did not attend 2HC, They are included in the count for participants remaining in Study at the time of EPIC-Norfolk 3 approach
Baseline characteristics of participants in EPIC-Norfolk. Participants who attended health examinations in both the first and third phases of EPIC-Norfolk (1HC + 3HC) are compared with those who were examined in the first phase only (1HC only)
| Variable | Men | Women | ||||
|---|---|---|---|---|---|---|
| 1HC+ 3HC | 1HC only | 1HC+ 3HC | 1HC only | |||
| ( | ( | ( | ( | |||
| Mean (SD)a | ||||||
| Age (years) | 56.6 (7.9) | 61.0 (9.5) | <0.001 | 55.2 (7.8) | 60.7 (9.5) | <0.001 |
| Height (cm) | 174.9 (6.5) | 173.6 (6.7) | <0.001 | 162.1 (6.0) | 160.4 (6.3) | <0.001 |
| Body mass index (kg/m2) | 26.1 (3.0) | 26.7 (3.4) | <0.001 | 25.5 (4.1) | 26.6 (4.4) | <0.001 |
| Systolic blood pressure (mmHg) | 134.2 (16.3) | 138.9 (18.1) | <0.001 | 129.4 (17.1) | 136.0 (19.4) | <0.001 |
| Total cholesterol (mmol/l) | 6.0 (1.1) | 6.1 (1.1) | 0.007 | 6.1 (1.1) | 6.4 (1.2) | <0.001 |
| Frequency, % ( | ||||||
| Education | ||||||
| No qualification | 22.0 (795) | 34.3 (2739) | <0.001 | 29.5 (1327) | 48.2 (4593) | <0.001 |
| O-level or equivalent (or above) | 78.0 (2819) | 65.7 (5245) | <0.001 | 70.5 (3167) | 51.8 (4936) | <0.001 |
| Social class (% I-IIINM) | 65.0 (2333) | 55.4 (4324) | <0.001 | 67.5 (3001) | 58.5 (5393) | <0.001 |
| Smoking | ||||||
| Current | 8.7 (313) | 13.8 (1092) | 8.8 (392) | 12.6 (1187) | ||
| Ex-smoker | 49.7 (1792) | 56.7 (4492) | 30.3 (1354) | 33.2 (3123) | ||
| Never | 41.6 (1498) | 29.5 (2339) | <0.001 | 61.0 (2729) | 54.2 (5108) | <0.001 |
| Physical activity | ||||||
| Inactive | 23.1 (834) | 34.4 (2752) | 20.3 (914) | 35.3 (3363) | ||
| Moderately-Inactive | 26.1 (945) | 24.0 (1913) | 33.2 (1493) | 31.5 (3000) | ||
| Moderately-active | 25.0 (905) | 22.0 (1755) | 26.0 (1168) | 20.4 (1948) | ||
| Active | 25.8 (931) | 19.7 (1571) | <0.001 | 20.5 (920) | 12.9 (1226) | <0.001 |
| Median (IQR)c | ||||||
| Alcohol intake (units/week) | 7 (2.5, 14.5) | 6 (2, 14) | <0.001 | 2.5 (1, 7.5) | 2 (0.5, 6) | <0.001 |
Groups were compared using unpaired Student’s t-testa, chi squareb and Mann-Whitneyc tests as appropriate. 1HC, first health examination; 3HC, third health examination (EPIC-Norfolk 3); SD, standard deviation; IQR, interquartile range; I-IIINM: social class I-III Non-Manual.
Range of function and health observed in the EPIC-Norfolk 3 cohort
| Variables | Mean (SD) | Median (IQR) | ||
|---|---|---|---|---|
| Systolic blood pressure (mmHg) | 3860 | 136.4 (15.4) | 136.5 (126.5, 146.5) | |
| Total cholesterol (mmol/l) | 3604 | 5.0 (1.1) | 4.9 (4.2, 5.7) | |
| Body mass index (kg/m2) | 3850 | 27.1 (3.6) | 26.7 (24.7, 29.0) | |
| Derived full MMSE score | 3625 | 27.5 (1.4) | 28.0 (27.0, 29.0) | |
| Grip strength of strongest hand (kg) | 3812 | 39.1 (8.3) | 39.0 (33.5, 45.0) | |
| Intraocular pressure (mm/Hg) | 3753 | 16.2 (3.8) | 15.6 (13.5, 18.4) | |
| Smoking, % ( | ||||
| Current | 4.2 (159) | |||
| Ex-Smoker | 51.2 (1949) | |||
| Never Smoker | 44.6 (1695) | |||
| Physical Activity, % ( | ||||
| Inactive | 37.4 (1422) | |||
| Moderately-inactive | 25.0 (954) | |||
| Moderately active | 18.8 (713) | |||
| Active | 18.8 (714) | |||
| Alcohol intake (units/week) | 10.0 (2.0, 23.0) | |||
| Systolic blood pressure (mmHg) | 4758 | 135.9 (17.1) | 136.0 (124.5, 146.5) | |
| Total cholesterol (mmol/l) | 4369 | 5.7 (1.1) | 5.7 (5.0, 6.4) | |
| Body mass index (kg/m2) | 4753 | 26.6 (4.8) | 25.9 (23.3, 29.0) | |
| Derived full MMSE score | 4333 | 27.5 (1.5) | 28.0 (27.0, 29.0) | |
| Grip strength of strongest hand kg) | 4661 | 24.3 (5.6) | 24.5 (21.0, 28.0) | |
| Intraocular pressure (mm/Hg) | 4640 | 16.3 (3.5) | 16.1 (14.0, 18.4) | |
| Smoking, % ( | ||||
| Current | 4.5 (213) | |||
| Ex-Smoker | 29.8 (1400) | |||
| Never Smoker | 65.7 (3085) | |||
| Physical activity, % ( | ||||
| Inactive | 37.2 (1748) | |||
| Moderately-inactive | 32.2 (1513) | |||
| Moderately active | 17.0 (796) | |||
| Active | 13.6 (641) | |||
| Alcohol intake (units/week) | 4.0 (0.0, 12.0) | |||
SD, Standard Deviation; mmHg, millimetres of mercury; SF-MMSE, Short form MMSE Score; IOP, Intraocular pressure; IQR, Inter-quartile Range
Socio-demographic Employment status Self-rated health and diagnosis (including vision and hearing) Social networks and support, leisure activities and hobbies Activities of daily living Falls Medication Smoking and alcohol Self-perceived wealth and economic status |
Psychosocial measures Widespread pain using the Manchester Coding System Social life Loneliness Anxiety and depression Mood status Health Daily activities, lifetime events Childhood experiences, personal beliefs |
Self-report on physical activity behaviours in three domains: activity at home, work and recreation. Also, using Geographical Information Systems (GIS) |
Self-report on exposure to UV sunlight (lifetime and previous year) Skin reaction to sunlight exposure Tanning (including attitude towards UV exposure) Use of sun protection/skin care Natural hair colour (at age 20 years and current) |
7-day food diary and Food Frequency Questionnaire (FFQ) |
aNew measures in EPIC-Norfolk 3 (not applied at previous phases).
| Venous blood sample | Biomarkers included full blood count (platelets, total white blood count, neutrophils, basophils, eosinophils, monocytes, lymphocytes, total red blood cell count), mean corpuscular volume, hamatocrit, haemoglobin; glycated haemoglobin; lipid profile (total cholesterol, HDL LDL, triglyceride); vitamin C; creatinine; albumin; and C-reactive protein. Serum, plasma and whole blood also stored for future biochemical profiling and DNA extraction |
| Anthropometric measures | Standing height (Stadiometer, Chasmores, UK), weight, waist and hip circumference |
| Impedance/body fat | Body fat percentage measured using TANITA TBF-300 MA Body Composition Analyser (Tanita UK, Yiewsley, UK) |
| Physiological functions | Brachial pressure and heart rate measured with Accutorr PlusTM automatic sphygmomanometer blood pressure monitor (Datascope Medical, Huntingdon, UK). Also measured was Ankle Brachial Pressures |
| Ultrasound measurements of the calcaneus | Attenuation of broadband ultrasound(dB/MHz) and speed of sound (m/s) were measured three times on each foot with CUBA clinical instrument (McCue Ultrasonics, Winchester, UK) |
| Skin ageing | Digital Images of skin on face and hands taken and stored for future grading |
| Cognitive assessmen | Retrospective and prospective memory, attention and calculation, registration, new learning, language, executive function, proxy measure of IQ and visuospatial /constructional ability |
| Physical capability | Usual walking speed, standing balance, chair stands, grip strength using a Smedley’s Dynamometer (Scandidact, Kvistgaard, Denmark) |
| Objective measure of physical activity | Physical activity using a commercial accelerometer, the GT1M (Actigraph, Florida, USA) |
| Eye examination | Visual acuity using the LogMAR visual acuity chart 1 (Precision Vision, LaSalle, IL, USA), intraocular pressure using an AT555 Non-Contact Tonometer (Reichert, New York, USA) and later using the Ocular Response Analyzer (ORA, Reichert, New York, USA), axial length and anterior chamber depth using IOLMaster, (Carl Zeiss Meditech, Welwyn Garden City, UK), retinal nerve fibre layer thickness (GDx VCC, Zeiss, Dublin, CA, USA). Threshold visual field analysis was done with the Humphrey field analyser (Carl Zeiss Meditech), optic nerve head topography determined using the HRT II (Heidelberg Retina Tomograph, Heidelberg Engineering, Heidelberg, Germany), colour fundus photography of optic disc and macula using a Topcon non-mydriatic retinal camera TRC-NW6S and IMAGEnet Telemedicine System (Topcon Corporation, Tokyo, Japan) with a 10- megapixel Nikon D80 camera (Nikon Corporation, Tokyo, Japan). |
| Medication | Confirmation of medication by nurse using repeat prescription slips |
aNew measures in EPIC-Norfolk 3 (not applied at previous phases).